Patents by Inventor Sougato Boral

Sougato Boral has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10669265
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: June 2, 2020
    Assignee: ALLERGAN, INC.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Patent number: 10633373
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: December 15, 2017
    Date of Patent: April 28, 2020
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Patent number: 10011593
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: April 18, 2017
    Date of Patent: July 3, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • Publication number: 20180111921
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 26, 2018
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Publication number: 20180105515
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 19, 2018
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Patent number: 9868726
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: January 16, 2018
    Assignee: ALLERGAN, INC.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Publication number: 20170226094
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: April 18, 2017
    Publication date: August 10, 2017
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • Patent number: 9650366
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: May 16, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • Publication number: 20170107210
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: May 23, 2016
    Publication date: April 20, 2017
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Publication number: 20170096419
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: May 11, 2016
    Publication date: April 6, 2017
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • Patent number: 9567324
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: February 14, 2017
    Assignee: ALLERGAN, INC.
    Inventors: Sougato Boral, Shimiao Wang, Thomas C. Malone, Julie Wurster, Jie Shen, Michael Robinson
  • Patent number: 9403803
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: August 2, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Publication number: 20160194311
    Abstract: The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
    Type: Application
    Filed: March 14, 2016
    Publication date: July 7, 2016
    Inventors: Sougato Boral, Shimiao Wang, Thomas Malone, Julie Wurster, Jie Shen, Michael Robinson
  • Patent number: 9371314
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: June 21, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Patent number: 9359336
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: June 7, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • Patent number: 9353093
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Grant
    Filed: October 7, 2014
    Date of Patent: May 31, 2016
    Assignee: Allergan, Inc.
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Publication number: 20160102077
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: October 8, 2014
    Publication date: April 14, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Publication number: 20160102081
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4 and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 14, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang, Sandhya Rao, Rong Yang
  • Publication number: 20160102080
    Abstract: This invention is directed to compounds, which are useful as protein kinase (PK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders, metabolic diseases inflammatory disorders and neurodegenerative disorders.
    Type: Application
    Filed: October 9, 2014
    Publication date: April 14, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang
  • Publication number: 20160096828
    Abstract: This invention is directed to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, and X are as defined herein. The compounds of Formula I are useful as receptor tyrosine kinase (RTK) inhibitors and can be used to treat such diseases as cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases.
    Type: Application
    Filed: October 7, 2014
    Publication date: April 7, 2016
    Inventors: Sougato Boral, Thomas C. Malone, Shimiao Wang